An open-label, non-comparative, multicentre study to evaluate the acceptability of a new paediatric formulation of hydroxycarbamide in children with sickle cell disease
Latest Information Update: 21 Dec 2022
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Sponsors addmedica
- 19 Dec 2022 Status changed from recruiting to completed.
- 29 Apr 2022 New trial record